Introduction

In March 2020, Insulin was officially moved to biologic regulatory framework by US FDA. This coupled with new guidelines on relaxation in comparator clinical trials data may prove to be boon for entry of cheaper Insulin Biosimilars in the US. Otherwise the many diabetes patients in the US are unable to afford treatments due to very expensive Biologics, and some industry reluctance towards giving easy walk over to cheaper Biosimilars. The entry of interchangeable insulin biosimilars are expected to bring down cost of treatment. Whereas in EU the first insulin biosimilar was approved in 2014, and it was priced 15-35% lower than the Biologic. Currently EU and APAC together cover significant portion of insulin biosimilars market. Whereas the recent guidelines by US FDA may see new biosimilars getting approvals in the US market very soon.

As per some studies conducted in the UK the direct cost of managing diabetes in UK alone is close to GBP 14 Bn per year in 2018. As well as insulin alone costs NHS an estimated GBP 82 Mn per year. There are currently two biosimilars insulin available in UK i.e. 

• Insulin Glargine – Abasaglar by Eli Lilly (Sep 2015)
• Insulin Glargine – Semglee by Mylan (Nov 2018)
• Insulin Lispro – Insulin Lispro by Sanofi (Jun 2018)

Recent Updates

Sanofi have recently got positive review from EMA’s Committee for Medicinal Products for Human Use (CMPH) for authorization process for its Biosimilar, Insulin Aspart. The Biosimilar, insulin aspart 100 units/ml, is a version of Novo Nordisk’s NovoRapid. With this positive approval the company is more confident of getting MA for EU in very near future. Whereas post guidelines issues by US FDA other companies such as Biocon and Sandoz are pushing to get some of their products approved in US markets.
On the other hand the innovators such as NovoNordisk and Eli Lilly are also trying to bring their own products’ biosimilars, but the market sentiments remain grim since in many cases it is reported that those biosimilars are mostly not available in pharmacy stores.

Major Players

Competitive profiles will include companies like Novo Nordisk, Eli Lilly, Biocon, Sandoz, Sanofi, Mylan, Boehringer Ingelheim Gmb, Momenta Pharmaceuticals, etc.

To get a copy of Table of Contents (ToC), Report Blue Print or Sample Copy please Click HERE

To get a copy of List of Deliverables please share your requirements HERE

We offer customized reports as per our customers requirements. This covers a 360 degree deliverable scope study such as:

• You may need some additional insights in MARKET RESEARCH report as per your decision making team. Please let us know your requirements.
• You may require a SOURCING INTELLIGENCE report for this topic as per requirement for your sourcing/procurement teams. You may let us know your requirements and we will prepare a feasibility study for your perusal.
• You may require a hybrid report consisting of Market Research Data and Sourcing Intelligence inputs in one report. Please let us know your requirement and we will share the list of deliverables for this Market Intelligence.
• You may require an Extensive and Potential List of Suppliers or Potential List of Customers Or List of other Stakeholders. Please feel to let us know and we will share the scope study.

This section covers very brief quick reports as a scale down version of original Market Research report. You may be any of the following:

• You may require market data in a quick interval of time, and you don’t have further need.
• You are a research scholar and you need market research in brief for some project
• Due to budget constraints you may need market research report in brief

Please don’t worry and write to us HERE

For any other discussion such as related to various reports, future business requirements, feasibility discussion, etc. Or for talk to our sales team executive please feel free to reach out to us HERE